CBAY

Cymabay Therapeutics
CBAY

Overview Fund Activity
Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

189 hedge funds and large institutions have $1.61B invested in Cymabay Therapeutics in 2023 Q3 according to their latest regulatory filings, with 63 funds opening new positions, 57 increasing their positions, 52 reducing their positions, and 24 closing their positions.

Holders
189
Holders Change
+38
Holders Change %
+25.17%
% of All Funds
3.01%
Holding in Top 10
12
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+33.33%
% of All Funds
0.19%
New
63
Increased
57
Reduced
52
Closed
24
Calls
$35M
Puts
$32.9M
Net Calls
+$2.15M
Net Calls Change
-$1.47M

Top Buyers

1
RCM
1
RA Capital Management
Massachusetts
$103M
2
Holocene Advisors
2
Holocene Advisors
New York
$46.5M
3
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$36.2M
4
FAM
4
Fred Alger Management
New York
$32.4M
5
Jennison Associates
5
Jennison Associates
New York
$53M

Top Sellers

1
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$13.6M
2
OCA
2
Octagon Capital Advisors
New York
$45.8M
3
CC
3
Commodore Capital
New York
$0
4
Millennium Management
4
Millennium Management
New York
$2.14M
5
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$101M
Name Holding Trade Value Shares
Change 		Shares
Change %
Balyasny Asset Management
26
Balyasny Asset Management
Illinois
$15.3M -$10.3M -690,679 -40%
Northern Trust
27
Northern Trust
Illinois
$15M +$479K +32,113 +3%
LCM
28
Lynx1 Capital Management
Puerto Rico
$14.8M -$3.14M -210,889 -18%
EA
29
Emerald Advisers
Pennsylvania
$14.7M +$14.7M +983,775 New
Invesco
30
Invesco
Georgia
$14M +$295K +19,789 +2%
BCLSI
31
Bain Capital Life Sciences Investors
Massachusetts
$13.6M -$23.6M -1,586,031 -63%
EMFAT
32
Emerald Mutual Fund Advisers Trust
Pennsylvania
$12.1M +$12.1M +809,738 New
ACM
33
Altium Capital Management
New York
$11.9M +$1.96M +131,298 +20%
Charles Schwab
34
Charles Schwab
California
$11.9M +$7.96M +533,821 +202%
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$11.9M +$1.57M +105,608 +15%
Nuveen Asset Management
36
Nuveen Asset Management
Illinois
$10.4M +$5.97M +400,517 +134%
Two Sigma Advisers
37
Two Sigma Advisers
New York
$9.96M -$7.28M -488,400 -42%
Arrowstreet Capital
38
Arrowstreet Capital
Massachusetts
$9.37M +$9.37M +628,303 New
MB
39
MPM BioImpact
Massachusetts
$9.11M +$9.11M +610,770 New
SCM
40
Silverarc Capital Management
Massachusetts
$8.8M +$6.41M +430,000 +269%
Goldman Sachs
41
Goldman Sachs
New York
$8.36M -$185K -12,384 -2%
HRCM
42
Hood River Capital Management
Florida
$7.64M +$7.64M +512,411 New
Morgan Stanley
43
Morgan Stanley
New York
$7.57M -$4.71M -316,228 -38%
Deutsche Bank
44
Deutsche Bank
Germany
$6.8M -$5.51M -369,851 -45%
ACP
45
Acuta Capital Partners
California
$6.23M -$179K -12,000 -3%
WP
46
Woodline Partners
California
$6.12M +$1.86M +124,998 +44%
EI
47
EAM Investors
California
$5.69M +$133K +8,940 +2%
Bank of New York Mellon
48
Bank of New York Mellon
New York
$5.6M -$28.9K -1,938 -0.5%
JPMorgan Chase & Co
49
JPMorgan Chase & Co
New York
$5.41M -$906K -60,774 -14%
MAP
50
Moody Aldrich Partners
Massachusetts
$4.86M +$3.14M +210,637 +183%
1
2
3 4 5